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Abstract
Background: Small quantities of RNA (1–4 µg total RNA) available from biological samples
frequently require a single round of amplification prior to analysis, but current amplification
strategies have limitations that may restrict their usefulness in downstream genomic applications.
The Eberwine amplification method has been extensively validated but is limited by its ability to
produce only antisense RNA. Alternatives lack extensive validation and are often confounded by
problems with bias or yield attributable to their greater biological and technical complexity.
Results: To overcome these limitations, we have developed a straightforward and robust protocol
for amplification of RNA in the sense orientation. This protocol is based upon Eberwine's method
but incorporates elements of more recent amplification techniques while avoiding their
complexities. Our technique yields greater than 100-fold amplification, generates long transcript,
a n d  p r o d u c e s  m R N A  t h a t  i s  w e l l  s u i t e d  f o r  use with microarray applications. Microarrays
performed with RNA amplified using this protocol demonstrate minimal amplification bias and high
reproducibility.
Conclusion: The protocol we describe here is readily adaptable for the production of sense or
antisense, labeled or unlabeled RNA from intact or partially-degraded prokaryotic or eukaryotic
total RNA. The method outperforms several commercial RNA amplification kits and can be used
in conjunction with a variety of microarray platforms, such as cDNA arrays, oligonucleotide arrays,
and Affymetrix GeneChip™ arrays.
Background
The increased use of microarray expression profiling to
study both the molecular biology of cancer and the cellu-
lar physiology of difficult-to-isolate cell types has led to a
growing need for methods that allow the use of limiting
quantities of RNA. Small surgical biopsies, fine needle
aspirates, cyto-lavages, punch biopsies and blood samples
often yield only 1–4 µg quantities of RNA as starting mate-
rial for expression profiling. This limitation has prompted
the development of amplification methods that produce
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the quantities of RNA required for microarray analysis.
Changing requirements for the type and quantity of
amplified RNA, driven by evolving microarray technolo-
gies, have led to the development of novel amplification
strategies. While current methods are capable of deliver-
ing high-yield RNA amplification, this is often only
achieved after complex priming strategies (for example,
involving 4 or more primers) are coupled with multiple
rounds of PCR and/or in vitro transcription, resulting in
time consuming and costly protocols. Here, we present an
overview of RNA amplification strategies, identify key lim-
itations to existing techniques, and describe a simple,
robust, and cost-effective strategy for single round ampli-
fication of RNA in the sense orientation.
RNA amplification methods
Early attempts to amplify RNA employed a strategy based
upon the Polymerase Chain Reaction (PCR) [1-4]. These
methods relied on the terminal transferase activity of
reverse transcriptase to allow addition of primer sites to
the 3' end of reverse-transcribed, first-strand cDNA. Mul-
tiple rounds of PCR primed from this site and from the
poly-(A)+  sequence on the second-strand cDNA could
then be used to facilitate amplification. These methods
were confounded by differential amplification of cDNA
and by introduction of errors by Taq  polymerase. This
problem prompted the development of a linear, T7-based
in vitro transcription (IVT) method by Van Gelder and
Eberwine [5-7].
In what has now become known as the "Eberwine
Method," RNA templates are primed with an oligo(dT)
primer that has been 5' modified to contain a promoter
for the T7 RNA polymerase and are subsequently reverse
transcribed into first-strand cDNA. The RNA-cDNA hybrid
is then treated with E. coli RNAse H, and priming for sec-
ond-strand cDNA synthesis occurs by either RNA nicking
and priming or cDNA hairpinning6. Second-strand cDNA
synthesis is carried out with E. coli DNA polymerase and
E. coli DNA ligase followed by blunt-ending with T4 DNA
polymerase. Transcription and amplification are then
accomplished using the T7 RNA polymerase, which binds
to the T7 promoter introduced during first-strand cDNA
synthesis, producing antisense RNA (aRNA).
Technical revisions of the Eberwine method have
included changes in first-strand primer concentration to
minimize the appearance of non-sequence dependent
RNA in the amplified product [8], supplementation of
second-strand priming with random primers to improve
its efficiency, and modifications that allow multiple
rounds of IVT to augment yield [6,9,10]. Concerns regard-
ing the fidelity of amplification with these methods stem
from the 3' bias introduced by the use of the promoter-
modified oligo(dT) primer during first-strand cDNA syn-
thesis, and questions remain over the degree to which this
amplified RNA reflects the true transcriptome of the
unamplified sample. To correct for this potential bias,
three alternatives have been developed to the Eberwine
protocol.
One such alternative [11] is based upon the Eberwine
approach, but second and subsequent rounds of amplifi-
cation are primed with random nonamer primers modi-
fied by the addition of an upstream T3 promoter sequence
(T3N9 primer). IVT from this T3 promoter prevents seri-
ally compounding the 3' bias introduced by the oligo(dT)
primer across multiple rounds of amplification. The T3N9
primer has also been used to prime the initial round of
reverse transcription, a modification that is useful for
amplifying partially-degraded samples of RNA [12]. In
this case, the method sacrifices the ability to selectively
amplify mRNA for the versatility generated by the random
priming and subsequent amplification of any RNA
sequence present in the sample.
A second alternative to the Eberwine method is the "tem-
plate-switching" (TS) strategy [13]. This technique centers
on the observation that the Moloney murine leukemia
virus reverse transcriptase (MMLV-RT) adds an oligo(dC)
region to the 3' end of first-strand cDNA after reaching the
terminal end of an RNA template [14]. When an oligo(G)
primer is added to the second strand RT reaction, it will
hybridize with this oligo(dC) sequence, and the MMLV-
RT will switch strands (the "template-switch") and con-
tinue the reverse transcription reaction. This strategy can
be used to append a T7 promoter to the 5' end of the
oligo(G) primer[13,15], facilitating RNA amplification by
IVT. Yield can be further improved by combining this
technique with PCR amplification after cDNA synthesis
[16] for bulk production of amplified RNA [17]. Several
variations on this theme involving changes in the primers
and in the details of the PCR amplification have been
described, all of which rely on a combination of TS prim-
ers and PCR-based amplification to produce large
amounts of amplified RNA [18,19].
A third recently introduced alternative is Ginsberg's Ter-
minal Continuation (TC) technique [20]. In this
approach, the initial reverse transcription reaction is
primed with a mixture of an oligo(dT) primer and a mod-
ified TC primer. The former primes the reverse transcrip-
tion of mRNA, while the latter is essentially a T7
promoter-containing GC-rich sequence that primes sec-
ond strand cDNA synthesis. According to Ginsberg, the
"likely mechanism (for this incorporation) is that the TC
primer binds preferentially to GC-rich CpG islands flank-
ing 5' regions of DNA that contain promoter sequences."
[21] Initial reports of the results of TC amplification show
promise for linear amplification of high-quality RNA, butBMC Genomics 2005, 6:27 http://www.biomedcentral.com/1471-2164/6/27
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extensive validations of this method have yet to be
conducted.
Validity of amplified RNA in microarray applications
The degree to which the pool of amplified RNA generated
by these methods reflects the unamplified sample from
which it is derived is an obvious concern for microarray
applications and other downstream analyses, and the his-
tory of attempts to validate RNA amplification methods is
summarized by Nygaard et al. [22]. Briefly, they note that
a combination of Northern blotting, dot blot differential
screening of cDNA probes synthesized from aRNA, inter-
nal RNA standards, hierarchical clustering, qRT-PCR, sub-
group analysis, and ratio-intensity (RI) plot analysis has
lead to the conclusions that relative expression levels are
well-preserved after 1–3 rounds of amplification, that
important over- or under-expressed genes are detectable
after amplification, and that amplification may actually
improve detection of RNA present in low copy number.
However, they noted that few studies quantitatively com-
pare total RNA and amplified RNA, that the true sources
of amplification biases have not been thoroughly investi-
gated, and that the degree to which "noise" affects the dif-
ferences in these profiles has not been adequately
assessed. Accordingly, they conducted multiple hypothe-
sis testing based upon t-tests and ANOVA analysis of sev-
eral technical parameters to study the nature and the
magnitude of biases and variability associated with the
use of amplified RNA in microarray expression profiling.
They observed that approximately 10% of genes showed
statistically significant differences in relative expression
level between amplified and their unamplified counter-
parts and noted that neither technical replication of
amplifications nor molecular characteristics of the sample
were the likely cause of these observed differences.
Despite these differences, they stated that the increased
quantity and purity of mRNA hybridized in studies using
amplified RNA increases overall fluorescence intensity
and improves detection of low-abundance messages.
Because they noted that more that 50% of the amplified
RNA showed log2(ratio) differences within ± 0.5 of the
unamplified RNA, they concluded that RNA amplification
is useful in expression profiling and is likely to assist in the
measurement of low-abundance RNA.
Despite the methodological validation provided by these
studies, only recently have statistically-based analyses
been used to compare RNA amplification methods in a
critical, head-to-head fashion. A study by Zhao [23] exam-
ined differences between T7-based amplification proto-
cols, including the Eberwine method and the template
switch (TS) technique, where these methods were used to
amplify RNA extracted from tumor samples rather than
from the idealized situation of cell lines. They observed
that the use of TS strategies does not improve the fidelity
of RNA amplification versus the Eberwine method, that
there is good correlation between samples after amplifica-
tion, that the overall bias introduced by T7-based amplifi-
cation strategies is uniformly low, and that the results are
reproducible. Their overall conclusion was that T7-based
amplification protocols generate high-fidelity, amplified
antisense RNA that is suitable for use in cDNA microarray
analysis.
Limitations of current amplification protocols
It is currently accepted that RNA amplification strategies
based on the Eberwine method maintain relative mRNA
levels between samples when amplifying from either total
RNA or poly(A)+ RNA [24,25], are useful with low micro-
gram quantities of starting RNA [26], and are capable of
preserving differential expression profiles when used in
conjunction with microarray analysis [13]. Accordingly,
efforts have become increasingly focused upon develop-
ing an optimized protocol that minimizes amplification
bias, provides versatility, and reduces technical complex-
ity. While current commercial kits and published proto-
cols are making progress to these ends, we feel that several
important dimensions have been overlooked, limiting
their utility.
First, most commercial protocols produce RNA only in
the antisense orientation. With the emergence of spotted
oligonucleotide arrays and mixed cDNA/oligo arrays [27],
appropriate orientation of amplified RNA is an important
experimental consideration. While TS and TC protocols
can be modified to produce sense RNA, this generally
comes at the cost of increased technical and biological
complexity but adds no demonstrable benefit over the
Eberwine strategy. Second, many current protocols rely on
multiple rounds of IVT and/or PCR to produce amplified
RNA, and even a few rounds of this amplification has the
potential to introduce sequence error [6] or systematic
bias [28]. While some applications, such as laser capture
microdissection, may produce only picogram quantities
of RNA and thus require extensive amplification, it should
be noted that even small biopsy samples frequently yield
low microgram quantities of RNA and thus may require
only a single round of amplification. Finally, the increas-
ing complexity of many amplification protocols creates
logistical problems when implementing them for large-
scale projects. Protocols that require multiple rounds of
amplification can accumulate material and labor costs
that quickly exceed those associated with the actual micro-
array analysis, and amplification can become a "rate-lim-
iting" (or "cost-limiting") factor in study design.
Additionally, the number of enzymes, reagents, and cus-
tom primers continues to increase as protocols become
more complex, a situation which is equally undesirable.
We believe that a protocol that addresses these limitationsBMC Genomics 2005, 6:27 http://www.biomedcentral.com/1471-2164/6/27
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and provides a versatile and robust method for RNA
amplification is needed.
Goals for a revised RNA amplification protocol
Our goal was to develop a strategy based upon the Eber-
wine method but with the ability to produce sense RNA
from small quantities of total or poly-(A)+ RNA extracted
from both ideal samples (e.g. cell line RNA) and "real-
world" samples (e.g. tumors or tissues). This protocol
should avoid the need for PCR steps and should require a
minimum number of primers (two). Additionally, the
protocol should be cost-effective, efficient, and techni-
cally simple to conduct. Finally, the method should give
results consistent with similar amplification techniques
when used with subsequent microarray analysis. We
believe these criteria have been met with our protocol,
which consequently will be useful in a variety of labora-
tory applications.
Results
Priming efficiency and cDNA yield
Quantitation of first strand cDNA after hydrolysis of the
cDNA/RNA hybrid shows that priming with the T7-
Oligo(dT) promoter/primer followed by reverse transcrip-
tion produces cDNA that totals 5–10% by mass of the
original mass of total RNA (data not shown). This is con-
sistent with the average percentage of mRNA in the total
RNA sample and therefore suggests that priming proceeds
efficiently and that first strand cDNA synthesis success-
fully copies the population of mRNA in the original total
RNA sample. Quantitation of second strand cDNA after
priming with the T3N9 promoter/primer indicates a
120% increase in mass versus the mass of the first strand
cDNA (data not shown). This suggests that second strand
priming proceeds efficiently and that the first strand
cDNA is successfully converted to double stranded cDNA
by the second strand synthesis reaction. The extra mass (in
excess of 100%) is attributable to the use of random non-
amer primers which initiates synthesis at multiple posi-
tions along each first-strand cDNA template.
Median transcript length
While inherent constraints of reverse transcription limit
the amount of truly "full-length transcript" produced dur-
ing any RNA amplification scheme, it is nonetheless desir-
able for an amplification method to favor the production
of long transcript. RNA amplified using our method has a
median length of 794 nucleotides (range: 70–9000 nt)
suggesting that this method is capable of preserving long
transcript during amplification (Table 2).
Quantitative yield
Our method produced an average ( ) of 26.3 µg of
amplified sense mRNA from 4 µg of total RNA (Table 2).
Assuming that 5% of the original sample of total RNA was
mRNA, this reflects a 130-fold amplification. The protocol
has been tested with as little as 1 µg of starting total RNA
and produces sufficient mRNA for microarray analysis (~2
µg) under these conditions (data not shown).
Amplification bias
Any amplification will introduce some degree of bias into
the population of amplified RNA. While recent reports
suggest that the magnitude of this bias may be relatively
unimportant as long as the bias is highly reproducible
[29], we feel that aggressively limiting any source of exper-
imental bias improves the quality of subsequent microar-
ray data. We systematically evaluated the performance of
RNA amplified using this protocol against identical
hybridizations from unamplified RNA. Log2(ratio) plots
of fluorescence intensity in amplified versus unamplified
samples were constructed and analyzed for correlation as
described above. Our results show that the amplification
bias introduced by this method is small, as reflected in the
high average correlation coefficient ( ) between expres-
sion profiles from amplified and unamplified RNA sam-
ples (  = 0.8009, Table 3, Figure 2).
Reproducibility
We evaluated the reproducibility of this method and the
consistency of the propagation of the amplification bias
by comparing the expression profiles of hybridizations of
three independently amplified RNA samples. Log2(ratio)
plots of fluorescence intensity were constructed and
analyzed as described above. Our results demonstrate a
high degree of correlation between independent replicates
(  =.9446, Figure 3) and a narrow dispersion (σ 2 =
Table 2: Yield and transcript length of amplified RNA produced by three amplification methods. Values in parentheses represent p-
values from t-test comparing the value against that of the study protocol.
Study Protocol RiboAmp Protocol (p-value 
vs. Study Protocol)
BDSMart Protocol (p-value vs. 
Study Protocol)
Mean yield from 4 µg total RNA ( , µg) 26.29 71.56 (<0.04) 4.87 (<<0.0001)
Median amplified RNA length (nt) 794 507 (<0.003) 764 (0.88)
x
x
r
r
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0.00023, CV = 1.60%), suggesting that the amplification
is highly reproducible and that the amplification bias is
introduced consistently when the protocol is repeated.
Comparison with commercial amplification kits
We compared these results to results from the RiboAmp
mRNA amplification kit (Arcturus), which produces anti-
Table 3: Statistical analysis of microarray data generated by comparing hybridizations of amplified RNA samples to identical 
hybridizations of unamplified (total RNA) samples. Values in parentheses represent P-values from t-test comparing the value to that of 
the study protocol.
Study 
Protocol
RiboAmp Protocol (p-value 
vs. Study Protocol)
BDSmart Protocol (p-value 
vs. Study Protocol)
Mean Correlation Coefficient ( ) 0.8009 0.7202 (<0.01) 0.7679 (0.23)
Mean % of elements with absolute difference of ± 2 log2 units 0.34 1.34 (<0.02) 0.60 (0.56)
Mean % of elements with absolute difference of ± 1.5 log2 units 1.31 4.05 (<0.05) 1.63 (0.67)
Mean % of elements with absolute difference of ± 2 log2 units 5.44 12.54 (<0.02) 6.52 (0.61)
Mean % of amplified array elements within ± 1 log2 unit 94.56 87.46 (<0.02) 93.48 (0.61)
Correlation between expression profiles of RNA samples amplified using the study protocol and corresponding unamplified  RNA samples demonstrates a low degree of amplification bias Figure 2
Correlation between expression profiles of RNA samples amplified using the study protocol and corresponding unamplified 
RNA samples demonstrates a low degree of amplification bias.
r
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sense RNA using a version of the Eberwine method, and
from the BDSmart mRNA amplification kit (BD Bio-
sciences), which produces sense RNA using a template-
switching strategy. Both protocols were carried out accord-
ing to the manufacturer's specifications using 4 µg of the
pooled cell line RNA and the glioblastoma RNA as the
starting material for amplification. The final yield of each
method was measured using the NanoDrop spectropho-
tometer, the median size of the amplified mRNA from
each kit was assayed using the Bioanalyzer 2100 (Agilent),
and the amplification bias of each method was assessed
using microarray analysis (as described above).
Three independent replicates were conducted for each
method, and the reproducibility of the amplification was
assessed as described above. The mean correlation coeffi-
cient ( ) and the dispersion of each group (σ 2, CV) were
calculated, demonstrating a high degree of reproducibility
for both the RiboAmp (  = 0.950, σ 2 = 0.0004, CV =
2.09%) and the BDSmart (  = 0.895, σ 2 = 0.0010, CV =
3.47%) protocols. These results suggest that subsequent
comparisons of our amplification method to these com-
mercial techniques are not confounded by individual var-
iability among replicates. Additionally, the strong
correlation between independent replicates of our
method (see above) and of these commercial techniques
suggests that performing additional independent
replicates would not add significant statistical power to
subsequent comparisons.
The average yield from our method (  = 23.6 µg) was less
than that of the Arcturus RiboAmp method (  = 71.6 µg,
p < 0.04) but greater than that of the BDSmart method (
= 4.87 µg, p = 1.7 × 10-14). The decreased yield versus the
Arcturus RiboAmp method is expected, because IVT with
the T7 promoter (production of antisense RNA, Arcturus
method) proceeds more efficiently than IVT with the T3
Correlation between independent replicates of expression profiles of RNA samples amplified using the study protocol demon- strates the high degree of reproducibility of the method Figure 3
Correlation between independent replicates of expression profiles of RNA samples amplified using the study protocol demon-
strates the high degree of reproducibility of the method.
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promoter (production of sense RNA, our method). The
improved yield over the BDSmart method is notable con-
sidering that both of these methods involve production of
amplified sense RNA (Table 2).
The median length of the amplified RNA from our
method (794 nt) was greater than that of the Arcturus
RiboAmp method (507 nt, p < 0.003) and comparable to
that of the BDSmart amplification method (764 nt, p =
0.88) (Table 2). The correlation between expression pro-
files of amplified and unamplified RNA was 10.6% better
following amplification with our method (  = 0.8009)
versus amplification with the Arcturus RiboAmp method
(  = 0.7202, p < 0.01) and was comparable to the
correlation after amplification with the BDSmart method
(  = 0.7679, p = 0.15) (Table 3).
Discussion
The emergence of methods to study the transcriptome ini-
tially necessitated the production of relatively large quan-
tities of RNA from experimental systems, and Eberwine
and Van Gelder's T7-based system of In vitro
Transcription5–6 became the first standard protocol for
RNA amplification designed to fulfill these requirements.
The evolution of microarray technology and other RNA
techniques have imposed requirements on the type,
length, and/or orientation of the starting RNA. Addition-
ally, the growing interest in medical and microbial
genomics now requires that data be collected from sam-
ples that are becoming progressively smaller and more
difficult to acquire. This changing role for RNA amplifica-
tion has catalyzed the development of multiple institu-
tional and commercial amplification protocols, all of
which claim to be high-yield, low-bias techniques capable
of amplifying RNA with the specific characteristics
required for downstream applications.
Template switching, terminal continuation, and other
novel techniques for RNA amplification that have been
developed over the past five years have become increas-
ingly technically complex, and we feel that this is a
significant disadvantage. In particular, they stray from the
Eberwine approach, which has been extensively validated,
and often rely on the use of proprietary (i.e. unspecified)
enzymes, primers, and reaction components, which limit
the utility of the methods (as well as protocol modifica-
tion and fine-tuning). While proponents of these meth-
ods argue that the limitations are offset by improved yield,
production of long transcript, reproducibility, and
reduced amplification bias, we have found in practice that
no single protocol is able to perform consistently in all
four areas.
The technique that we have described affords the advan-
tages of all of the aforementioned protocols while elimi-
nating the major limitations and controlling the technical
complexity. Several aspects of this protocol make it a
robust tool that we believe will be useful in conjunction
with a variety of experimental systems and downstream
applications. First, the method we present is based upon
the Eberwine technique. The methods are both straight-
forward and validated and do not require the use of cus-
tom enzymes, multiple (more than 2) proprietary
primers, or PCR steps to complete the amplification. Sec-
ond, this new method produces amplified mRNA in the
sense orientation and can be used for production of aRNA
with minor modification. This corrects for the down-
stream limitations imposed by antisense amplification in
both the original Eberwine method and the Arcturus
RiboAmp kit and allows amplified mRNA produced by
our method to be used in conjunction with both cDNA
(sense and antisense orientation) and long oligonucle-
otide (sense orientation) arrays. Third, our method
requires only one round of amplification to produce RNA
in the sense orientation. We believe that this represents a
significant advantage over previously described, T7-based
amplification strategies (most notably the method of
Xiang [11]), where the modifications necessary for pro-
ducing sense RNA require a minimum of two rounds of
amplification. Fourth, our method produces sufficient
amplified sense RNA for multiple microarray analyses
after a single round of amplification from as little as 1 µg
of total RNA. This yield is significantly higher than the
BDSmart amplification kit and we have demonstrated
that our method produces amplified mRNA that performs
at least as well as the BDSmart amplification kit and supe-
rior to the Arcturus RiboAmp protocol in microarray
applications.
Another advantage of our protocol is that it is readily
adaptable to a variety of experimental systems. The
approach that we have described synthesizes amplified
RNA from eukaryotic total RNA in the sense orientation.
However, because this method adds unique promoters to
both the first and second cDNA strand (T7 and T3, respec-
tively), either orientation of RNA can be produced from
the same population of cDNA simply by selecting the
appropriate RNA polymerase for IVT. Moreover, changing
the two primers allows the protocol to be adapted to pro-
duce sense or antisense RNA from either prokaryotic or
eukaryotic total RNA without any additional adjustments.
The protocol can also be modified for use with either T3
or T7 IVT systems by changing the promoter sequence of
the promoter-modified primer, it can be used to salvage
partially-degraded RNA (as described by Xiang [11]), and
it can be used for indirect RNA labeling protocols by sub-
stituting modified ribonucleotide bases into the IVT mix.
Table 4 summarizes the primer pairs used for these alter-
nate strategies, and Table 1 gives the necessary primer
sequences. We have successfully tested a variety of these
r
r
rBMC Genomics 2005, 6:27 http://www.biomedcentral.com/1471-2164/6/27
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strategies and have achieved similar degrees of bias, repro-
ducibility, and yield (data not shown). We believe that the
ease with which this protocol can be adapted to a variety
of experimental systems is a major advantage.
In clinical and research settings using laser capture micro-
dissection or other strategies where very small amounts of
starting RNA (10–100 ng) are available, multiple rounds
of amplification may still be necessary. A final advantage
of our protocol, as discussed previously, is that a second
round of amplification can be easily incorporated and can
be used to produce additional RNA in either the sense or
antisense orientation. Future testing of this protocol will
focus on the quantity and fidelity of the RNA population
after multiple rounds of amplification and will include
appropriate comparisons to commercial, multi-round
techniques. However, the purpose of the present tech-
nique is to minimize bias while maintaining yield after a
single round of amplification. In this setting, our results
show that our method outperforms two commercial, sin-
gle-step protocols when using identical quantities of
initial RNA. We believe the performance and versatility of
this method make it particularly beneficial to investiga-
tors attempting to conduct microarray analysis from 1–4
µg of initial RNA.
Neither this nor any other current strategy for RNA ampli-
fication is optimally suited to every experimental setting,
and each technique has its own advantages and
limitations. The challenge of selecting an amplification
strategy is choosing a method that provides sufficient
amplification and appropriate RNA orientation for down-
stream requirements yet minimizes the labor, cost, and
bias introduced by the process. The method that we have
described has been designed and validated for use in
experiments where microarray analysis is to be performed
with approximately 1 µg of starting total RNA. In this set-
ting, our method produces a population of amplified
RNA having minimal and consistent amplification bias,
orientation compatible with both spotted cDNA and oli-
gonucleotide arrays, and quantity sufficient for several
downstream assays from a single amplification. Addition-
ally, the protocol we present here can be easily adapted for
use in a variety of experimental systems. This includes
production of either sense or antisense RNA in prokaryo-
tic or eukaryotic systems (simply changing one or both
primers). None of these variations require multiple
rounds of amplification to produce RNA of a specific ori-
entation, but the protocol can easily be modified to ena-
ble multiple rounds when necessary.
Finally, we would like to note that there are some limita-
tions to the method we have outlined here. Readers may
note that several amplification strategies have been
reported to produce greater than 1,000-fold increases in
RNA yield, one aspect of our method that may be viewed
as a limitation is its ~130-fold amplification. However,
most higher-yield amplification strategies use multiple
Table 1: Primer sequences for study protocol and its variations.
Primer Name Sequence Concentration 
(ng/µL)
T3N9 5'-GCGCGAAATTAACCCTCACTAAAGGGAGANNNNNNNNN-3' 100
T7N9 5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGNNNNNNNNN-3' 100
Oligo(dT)24 5'-TTTTTTTTTTTTTTTTTTTTTTTT-3' 100
T3-Oligo(dT)24 5'-GCGCGAAATTAACCCTCACTAAAGGGAGATTTTTTTTTTTTTTTTTTTTTTTT-3' 100
T7-Oligo(dT)24 5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGTTTTTTTTTTTTTTTTTTTTTTTT-3' 100
Random Hexamer 5'-NNNNNN-3' 3000
Table 4: Primer strategies for alternate versions of the study protocol.
Type of Total RNA First Primer Second Primer IVT System† Type of Product Orientation of 
Product
Eukaryotic Oligo(dT)24, T7-Oligo(dT)24 T3N9 T3 mRNA Sense
T3-Oligo(dT)24 Random Hexamer T3 mRNA Antisense*
Prokaryotic (or Partially 
Degraded**)
Random Hexamer T3N9 T3 Total RNA Sense
T3N9 Random Hexamer T3 Total RNA Antisense
† T7 IVT systems may be used by changing the promoter sequence of the modified primer to a T7 binding sequence
* Modified Eberwine Amplification
** As described by Xiang11BMC Genomics 2005, 6:27 http://www.biomedcentral.com/1471-2164/6/27
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rounds of amplification and are subject to additional
amplification bias. While we recognize that researchers
using submicrogram quantities of starting material may
consider strategies incorporating multiple rounds of
amplification, in our experience even small tissue biopsies
yield more than 1 µg of total RNA. The ability to amplify
this quantity of RNA efficiently and effectively was one of
our major design considerations. In this setting, 130-fold
amplification produces more than enough RNA for multi-
ple downstream microarray analyses and confers the ben-
efit of reduced bias inherent in a single-round
amplification protocol.
Conclusion
We have developed a robust method for amplification of
mRNA in the sense orientation. This protocol is based
upon the Eberwine method and incorporates the advan-
tages of more recent amplification techniques while elim-
inating many of the limitations of these strategies. Our
method allows the production of sense mRNA with one
round of IVT, yields 130-fold amplification, preserves
long transcript, and produces mRNA that is well suited for
downstream microarray applications. Microarray assays
performed with RNA amplified using our protocol dem-
onstrate that the method results in low amplification bias
and is highly reproducible. Additionally, our method is
readily adaptable for the production of sense or antisense,
labeled or unlabeled RNA from intact or partially-
degraded samples of prokaryotic or eukaryotic total RNA.
The method outperforms several commercial RNA ampli-
fication kits and can be used in conjunction with a variety
of downstream microarray platforms (cDNA arrays, oligo-
nucleotide arrays, Affymetrix GeneChip™ assays). We feel
that these advantages make our method a robust tool with
the potential for application in a variety of research
settings.
Methods
Overview of the method
The protocol that we have designed is based on the Eber-
wine method but uses novel priming strategies to produce
amplified RNA in the sense orientation. First-strand cDNA
synthesis from total RNA is primed with an Oligo(dT)24
primer followed by heat denaturing and then cooling to
facilitate primer annealing. Reverse transcription pro-
duces cDNA-mRNA hybrids which are then subjected to
alkali hydrolysis to remove template mRNA. First-strand
cDNA (fs-cDNA) is separated from residual enzymes,
nucleotides, and mRNA fragments using a spin column
technique.
Second-strand cDNA synthesis is primed with random
nonamers containing an upstream T3 promoter sequence
(T3N9). The sample is heated to denature the fs-cDNA
and to eliminate secondary structure. The temperature is
rapidly dropped to the upper limit of the annealing range
and then ramped more slowly to a final temperature of
4°C. We believe that this strategy minimizes "self-prim-
ing" of the fs-cDNA and, in the absence of competitive
priming from RNA fragments, facilitates optimal anneal-
ing of the second-strand primer. Second-strand cDNA (ss-
cDNA) synthesis is carried out using E. coli DNA polymer-
ase and ligase followed by blunt-ending with T4 DNA
Polymerase. The double-stranded cDNA is purified using
a spin column technique, and in vitro transcription (IVT)
from the T3 promoter sequences incorporated into the ss-
cDNA produces amplified RNA in the sense orientation
(Figure 1).
Cell line RNA
Total RNA used in this study was derived from three cell
lines: PA-1 ovarian teratocarcinoma, CaOV-3 ovarian ade-
nocarcinoma, and U118MG glioblastoma. All cell lines
were grown in a monolayer under Dulbecco's minimum
essential medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. Cell lines were
held at 37°C in an atmosphere of 4% CO2 and main-
tained accordingly. When culture plates achieved ~90%
confluence, RNA was extracted and purified following
TIGR standard operating procedures based on the Trizol
method (Invitrogen) [30]. RNA extracted from all three
cell lines was pooled to create a RNA mixture with a final
relative composition of 42.56% CaOV-3 RNA, 29.89%
PA-1 RNA, and 27.55% U118MG RNA. Purity was verified
by measurement of OD260/280 and OD230/260 in TE (pH
8.0) using a NanoDrop spectrophotometer, and RNA
integrity was assessed by measurement of the 28S/18S
ratio with the Agilent Bioanalyzer 2100 using the Agilent
Total RNA Nano chip assay. The final values for the RNA
pool were: OD260/280 = 2.04, OD230/260 = 2.20, 28S/18S =
2.13, indicating high purity, non-degraded RNA. Superas-
In RNAse inhibitor (Ambion) was added to a final con-
centration of 1U/µL according to manufacturer's recom-
mendations. RNA was stored at -80°C until it was used in
the RNA amplification process.
RNA amplification protocol
All temperature controlled steps in this protocol were con-
ducted using a Peltier thermal cycler (PTC225 DNA
Engine Tetrad, MJ research) in thin-walled, nuclease-free
PCR tubes (BioRad). All enzymes, buffers, and other reac-
tion components were purchased from Invitrogen unless
otherwise noted. Four (4) µg of pooled total cellular RNA
(described above) was as starting material for the amplifi-
cations. Priming for first strand cDNA synthesis is carried
out by combining the total RNA with 1 µL of T7-
Oligo(dT) primers (100 ng/µL, Ambion) and 1 µL of
Superas-In RNAse inhibitor (20U/µL, Ambion). The mix-
ture is diluted to 17.8 µL in DEPC treated water, heated at
70°C for 10 minutes, and cooled to 4°C for five minutes.BMC Genomics 2005, 6:27 http://www.biomedcentral.com/1471-2164/6/27
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First strand cDNA synthesis is accomplished by adding 6
µL of 5× First Strand Buffer, 3 µL 0.1M DTT, 1.2 µL of
dNTP mix (50 mM), and 2 µL of SuperScript II reverse
transcriptase followed by incubation at 42°C for 2.5
hours. After incubation, the reaction is cooled to 4°C for
2 minutes. Template RNA is hydrolyzed by adding 10 µL
of 1N NaOH (Sigma) and 10 µL of 0.5M EDTA (Sigma)
followed by incubation at 65°C for 15 minutes. The pH is
subsequently neutralized by adding 10 µL of 1N HCl
(Sigma). Hydrolyzed RNA and residual dNTPs are
removed using the Minelute reaction cleanup kit (Qiagen)
according to the manufacturer's protocol. Two rounds of
elution from the column, each in 10 µL of Buffer EB (Qia-
gen) are performed to improve recovery.
Priming for second strand cDNA synthesis is accom-
plished by combining the eluted first-strand cDNA with 2
µL of random nonamer primers modified by the addition
of a T3 promoter sequence at the 5' end (T3N9 primer,
100 ng/µL, Table 1)11 (Operon) followed by incubation at
95°C for 3 minutes. Immediately following this incuba-
tion, the samples temperature is decreased as quickly as
possible to 50°C followed by a temperature ramp from
50°C to 4°C at the rate of 0.4°C/s (~120s ramp time) and
then a hold at 4°C for 2 minutes. Second strand cDNA
synthesis is accomplished by adding 7µL of 5× Second
Strand Buffer, 2 µL of dNTP mix (50 mM), 4 µL of E. coli
DNA polymerase I (10U/µL), and 1 µL of E. coli DNA
ligase (10U/µL) followed by incubation at 16°C for 2
Overview of study method for amplification of RNA in the sense orientation Figure 1
Overview of study method for amplification of RNA in the sense orientation
AAAAA - 3’ 5’ mRNA
TTTTT – T7 T7-Oligo(dT) or 
Oligo(dT) Primer
AAAAA - 3’ 5’ mRNA
TTTTT – T7 – 5’ 3’ fscDNA
3’ fscDNA
T3–NNN? T3–NNN?
AAAAA – aT7 -3’ 5’ sscDNA
3’ fscDNA
TTTTT – T7 – 5’
TTTTT – T7 – 5’
Reverse Transcription
Hydrolysis
Priming
Second Strand Synthesis
T3N9 Primer
T3
AAAA – aT7 – 3’ 5’
sRNA
5’
5’
5’
IVT – T3 Polymerase
5’
AAAA – aT7 – 3’
AAAA – aT7 – 3’
AAAA – aT7 – 3’BMC Genomics 2005, 6:27 http://www.biomedcentral.com/1471-2164/6/27
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hours. After incubation, blunt-ending is carried out by
adding 2 µL of T4 DNA polymerase (5U/µL) and
incubating at 16°C for 5 minutes. The reaction is termi-
nated by adding 3.5 µL of 0.5 M EDTA (Sigma). Double
stranded cDNA is purified using the Minelute reaction
cleanup kit (Qiagen) following the manufacturer's proto-
col. Two rounds of elution with Buffer EB (Qiagen) are
carried out to improve yield. The first elution is in 10 µL
of Buffer EB, and the second is in 7 µL of Buffer EB. This
provides the eluted cDNA in a final volume of 16 µL (cor-
rected for 1 µL of retention on the column), which is the
appropriate volume for use in the subsequent IVT
reaction.
In vitro transcription is achieved using the T3 MegaScript
kit (Ambion). A double reaction is used to improve yield,
so 16 µL of NTP mix, 4 µL of 10× Reaction Buffer, and 4
µL of T3 MegaScript Enzyme Mix are added to the sample.
The reaction is incubated at 37°C for 14 hours (over-
night). The amplified RNA is purified using either the
RNEasy Mini or the RNEasy Minelute kit (Qiagen) accord-
ing to the manufacturer's protocol. Superas-In RNAse
inhibitor (Ambion) is added to the amplified RNA to a
final concentration of 1U/µL according to the manufac-
turer's recommendations.
Assessment of products and intermediates
cDNA and RNA quantity and purity were assessed by
measurement of OD260/280 and OD230/260 in the corre-
sponding elution buffers (pH 8.0) using a NanoDrop
spectrophotometer. RNA length distribution and integrity
were assessed with the Agilent Bioanalyzer 2100 using the
Agilent Total RNA Nano chip assay. Agilent's Bioanalyzer
Expert 2100 software was used to quantify transcript
length, and the software's automatic integration tool was
used to determine the area under the curve. The median
transcript length for each method was taken as the point
at which half of the integrated area was achieved.
Microarray analyses
Microarray analysis was conducted to determine the mag-
nitude of amplification bias. Pooled human cell line RNA
(as described above) as well as RNA extracted from one
human glioblastoma were amplified as described. The
amplified sense RNA (2 µg) was used as the starting mate-
rial for synthesis of cDNA target, and a spiking control
consisting of RNA transcripts of 10 genes from the Arabi-
dopsis thaliana genome was added to each sample prior
to cDNA synthesis in order to provide a consistent posi-
tive reference in subsequent hybridizations28. cDNA target
synthesized from the cell line RNA was indirectly labeled
with Cy-5 while target derived from the glioblastoma was
labeled with Cy-3. The labeled cDNA from the cell line
pool and from the glioblastoma were cohybridized to
human 32,000 element spotted cDNA arrays. The array
production, cDNA synthesis, target labeling, and hybridi-
zation were conducted following TIGR standard operating
procedures [31]. Independent replicates were conducted
for all amplifications and hybridizations.
In order to compare our method to commercially-availa-
ble RNA amplification kits, microarray analysis was con-
ducted using identical pooled cell line and glioblastoma
RNA that was amplified with two commercial products
(RiboAmp kit, Arcturus; and BDSmart mRNA Amplifica-
tion kit, BD Biosciences). Amplification of 4 µg of total
RNA was carried out according to the manufacturer's pro-
tocol for both kits, and 2µg of amplified RNA from each
sample was used for microarray analysis as described
above. Independent replicates were conducted for all
amplifications and hybridizations.
Unamplified total RNA from both the pooled cell line and
the glioblastoma was used as the starting material for the
control arrays. Ten (10) µg of total RNA from each sample
was used for cDNA synthesis, and the remainder of the
protocol was carried out as described for the amplified
samples.
Data analysis
Microarray data was analyzed using the TIGR TM4 soft-
ware package for microarray analysis [32]. TIGR Spot-
finder was used to isolate spots on the arrays, correct for
background, and assess the reliability of spots for
downstream analysis. TIGR MIDAS was then used to
adjust the data by applying LOWESS normalization
[33,34] followed by standard deviation regularization
[33,35]. The Cy5 channel (pooled cell line sample) was
taken as the reference for all transformations. Normalized
values of fluorescence intensity (FI) were log2  trans-
formed, and   was calculated for
each array element. Assessments of bias were conducted
by comparing the log2(ratio) values for each element in
the amplified sample arrays to their counterparts in the
unamplified control arrays. Measurements of reproduci-
bility were conducted by comparing the log2(ratio) values
of corresponding elements in independent replicates.
Statistical methods
The degree of bias introduced by an amplification method
was assessed by plotting 
against the   and calculat-
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ing the correlation coefficient (r) for each independent
replicate. The mean correlation coefficient ( ) was calcu-
lated for each method, and differences between   for
each amplification method were tested for statistical
significance. Welch's T-Test [36] was used for all
comparisons to control for the possible heteroscedastic
nature of the original array data.
The degree of reproducibility of our amplification method
was assessed by plotting the log2(ratio) values for paired
hybridizations derived from independent amplifications
of the same starting RNA, calculating the correlation coef-
ficient (r) for a series of independent replicates, and com-
puting the mean correlation coefficient ( ).
Reproducibility was further investigated by calculating the
variance (σ 2) and the coefficient of variation
 for   (CV), which describe the dispersion
of the values contributing to  .
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